Literature DB >> 23190248

Hepatocellular carcinoma in uremic patients: is there evidence for an increased risk of mortality?

Yun-Hsuan Lee1, Chia-Yang Hsu, Cheng-Yuan Hsia, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin, Rheun-Chuan Lee, Yi-You Chiou, Teh-Ia Huo.   

Abstract

BACKGROUND AND AIM: The clinical aspects of patients with hepatocellular carcinoma (HCC) undergoing maintenance dialysis are largely unknown. We aimed to investigate the long-term survival and prognostic determinants of dialysis patients with HCC.
METHODS: A total of 2502 HCC patients, including 30 dialysis patients and 90 age, sex, and treatment-matched controls were retrospectively analyzed.
RESULTS: Dialysis patients more often had dual viral hepatitis B and C, lower serum α-fetoprotein level, worse performance status, higher model for end-stage liver disease (MELD) score than non-dialysis patients and matched controls (P all < 0.05). There was no significant difference in long-term survival between dialysis and non-dialysis patients and matched controls (P = 0.684 and 0.373, respectively). In the Cox proportional hazards model, duration of dialysis < 40 months (hazard ratio [HR]: 6.67, P = 0.019) and ascites (HR: 5.275, P = 0.019) were independent predictors of poor prognosis for dialysis patients with HCC. Survival analysis disclosed that the Child-Turcotte-Pugh (CTP) provided a better prognostic ability than the MELD system. Among the four currently used staging systems, the Japan Integrated Scoring (JIS) system was a more accurate prognostic model for dialysis patients; a JIS score ≥ 2 significantly predicted a worse survival (P = 0.024).
CONCLUSIONS: Patients with HCC undergoing maintenance dialysis do not have a worse long-term survival. A longer duration of dialysis and absence of ascites formation are associated with a better outcome in dialysis patients. The CTP classification is a more feasible prognostic marker to indicate the severity of cirrhosis, and the JIS system may be a better staging model for outcome prediction.
© 2012 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23190248     DOI: 10.1111/jgh.12062

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  5 in total

1.  ALBI grade in dialysis patients with hepatocellular carcinoma: prognostic impact and staging strategy.

Authors:  Shu-Yein Ho; Po-Hong Liu; Chia-Yang Hsu; Chih-Chieh Ko; Yi-Hsiang Huang; Chien-Wei Su; Cheng-Yuan Hsia; Rheun-Chuan Lee; Ming-Chih Hou; Teh-Ia Huo
Journal:  J Gastrointest Oncol       Date:  2021-04

2.  Discrepancy between serological and virological analysis of viral hepatitis in hemodialysis patients.

Authors:  Jer-Ming Chang; Chung-Feng Huang; Szu-Chia Chen; Chia-Yen Dai; Ming-Lun Yeh; Jee-Fu Huang; Hsing-Tao Kuo; Wan-Long Chuang; Ming-Lung Yu; Shang-Jyh Hwang; Hung-Chun Chen
Journal:  Int J Med Sci       Date:  2014-03-08       Impact factor: 3.738

3.  Hepatocellular carcinoma in hemodialysis patients.

Authors:  Chern-Horng Lee; Sen-Yung Hsieh; Chih-Chun Chang; I-Kuan Wang; Wen-Hung Huang; Cheng-Hao Weng; Ching-Wei Hsu; Tzung-Hai Yen
Journal:  Oncotarget       Date:  2017-04-16

4.  Clinical features of hemodialysis patients treated for hepatocellular carcinoma: Comparison between resection and radiofrequency ablation.

Authors:  Atsushi Hiraoka; Takashi Kumada; Kojiro Michitaka; Hidenori Toyoda; Toshifumi Tada; Koichi Takaguchi; Kunihiko Tsuji; Ei Itobayashi; Daichi Takizawa; Masashi Hirooka; Yohei Koizumi; Hironori Ochi; Koji Joko; Yoshiyasu Kisaka; Yuko Shimizu; Kazuto Tajiri; Joji Tani; Tatsuya Taniguchi; Akiko Toshimori; Shinichi Fujioka
Journal:  Mol Clin Oncol       Date:  2017-03-10

Review 5.  Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges.

Authors:  Hsuan Yeh; Chung-Cheng Chiang; Tzung-Hai Yen
Journal:  World J Gastroenterol       Date:  2021-07-14       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.